Feng Xu

US Patent:

6569461, May 27, 2003

Filed:

Apr 26, 2000

Appl. No.:

09/558800

Inventors:

Richard D. Tillyer - Cranford NJ
Paul J. Reider - Westfield NJ
Edward J. J. Grabowski - Westfield NJ
Feng Xu - Staten Island NY
Jose M. Vega - Trappe PA
Mandana Asgharnejad - Ambler PA

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A61K 900

US Classification:

424497, 424400, 424464, 424465, 424482, 424490

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

US Patent:

7009055, Mar 7, 2006

Filed:

Jul 19, 2002

Appl. No.:

10/484610

Inventors:

Feng Xu - Staten Island NY, US
Kimberly A. Savary - Rahway NJ, US
John M. Williams - Hillsborough NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07D 215/16

US Classification:

546177, 546180, 568 34, 568 28

Abstract:

A dibromomethyl moiety is converted to a sulfonylmethyl moiety by treatment with a sulfinic acid salt. For example, (methyl-sulfonyl)methyl bromo-quinoline is prepared by the treatment of dibromomethyl bromo-quinoline with a sulfinic acid salt.

US Patent:

7339054, Mar 4, 2008

Filed:

Feb 6, 2004

Appl. No.:

10/544575

Inventors:

Feng Xu - Staten Island NY, US
Matthew M Bio - London, GB
Cameron Cowden - Hoddesdon, GB
Kimberly A. Petrillo - Philadelphia PA, US
J. Michael Williams - Hillsborough NJ, US
Chunhua Yang - Edison NJ, US
Marjorie See Waters - Cranbury NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

C07H 19/14
C07D 487/00

US Classification:

536 2711, 536 272, 544262

Abstract:

A process is provided for the preparation of branched-chain ribonucleosides of formula (I):.

US Patent:

7902376, Mar 8, 2011

Filed:

Jan 22, 2009

Appl. No.:

12/321533

Inventors:

Feng Xu - Staten Island NY, US
Mary M. Kim - Cheltenham PA, US
Yoshinori Kohmura - Ibaraki, JP
Tricia Sladicka - Schenectady NY, US
Jonathan D. Rosen - Iowa City IA, US
Michael J. Zacuto - Jersey City NJ, US

Assignee:

Merck Sharp & Dohme Corp. - Rahway NJ
Banyu Pharmaceutical Co., Ltd. - Tokyo

International Classification:

C07D 498/04
C07D 487/04
C07D 309/10

US Classification:

548218, 548242, 5483605, 549419

Abstract:

A novel process is provided for the preparation of chiral trans-2,3-disubstituted 5-oxotetrahydropyrans of structural formula (I):.

US Patent:

20030176501, Sep 18, 2003

Filed:

Nov 13, 2002

Appl. No.:

10/293153

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US

International Classification:

C07C069/34
A61K031/225

US Classification:

514/548000, 560/146000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.

US Patent:

20030211151, Nov 13, 2003

Filed:

Apr 29, 2003

Appl. No.:

10/425154

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Jose Vega - Trappe PA, US
Mandana Asgharnejad - Ambler PA, US

Assignee:

Merck & Co., Inc.

International Classification:

A61K031/225
A61K009/22
A61K009/16
A61K009/50

US Classification:

424/468000, 514/548000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a compound selected from a dihydroxy open acid statin and a pharmaceutically acceptable salt or ester thereof in a delayed-release pharmaceutical dosage form to a patient in need of such treatment wherein substantial release of the compound from the dosage form is delayed until after passage of the dosage form through the stomach.

US Patent:

20050119343, Jun 2, 2005

Filed:

Nov 5, 2004

Appl. No.:

10/981866

Inventors:

Richard Tillyer - Cranford NJ, US
Paul Reider - Westfield NJ, US
Edward Grabowski - Westfield NJ, US
Feng Xu - Staten Island NY, US
Robert Wenslow - East Windsor NJ, US
Jose Vega - Trappe PA, US
Richard Varsolona - Scotch Plains NJ, US

International Classification:

A61K031/225
C07C069/66

US Classification:

514548000, 560180000

Abstract:

The instant invention provides methods and pharmaceutical compositions for inhibiting HMG-CoA reductase, as well as for treating and/or reducing the risk for diseases and conditions affected by inhibition of HMG-CoA reductase, comprising orally administering a therapeutically effective amount of a crystalline hydrated form of the calcium salt of dihydroxy open acid simvastatin to a patient in need of such treatment. Methods for making the calcium salt of dihydroxy open acid simvastatin are also provided.

US Patent:

59986255, Dec 7, 1999

Filed:

Jan 5, 1998

Appl. No.:

9/003050

Inventors:

Richard D. Tillyer - Westfield NJ
David M. Tschaen - Holmdel NJ
Feng Xu - Staten Island NY

Assignee:

Merck & Co., Inc. - Rathway NJ

International Classification:

C07D21170
C07D21172

US Classification:

546342

Abstract:

This invention relates to a process for the preparation of a key intermediate using an chiral additive to effect an asymmetric conjugate addition.